Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer
- 1 August 1996
- Vol. 120 (2) , 159-167
- https://doi.org/10.1016/s0039-6060(96)80283-2
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cathepsin D and Epidermal Growth Factor Receptor Immunohistochemistry does not Predict Recurrence of Prostate Cancer in Patients Undergoing Radical ProstatectomyJournal of Urology, 1996
- Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomyUrology, 1995
- Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancerHuman Pathology, 1995
- Cancer statistics, 1994CA: A Cancer Journal for Clinicians, 1994
- p53 Expression and Clinical Outcome in Prostate CancerBritish Journal of Urology, 1993
- Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic CarcinomaJournal of Urology, 1993
- An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research TeamPublished by American Medical Association (AMA) ,1993
- Consensus review of the clinical utility of dna content cytometry in prostate cancerCytometry, 1993
- Infrequent RAS oncogene mutations in human prostate cancerThe Prostate, 1992
- Monoclonal antibody Ki‐67: its use in histopathologyHistopathology, 1990